Journal
INFLAMMATION
Volume 44, Issue 1, Pages 243-248Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10753-020-01326-6
Keywords
T2 peptide; Chronic prostatitis; chronic pelvic pain syndrome; Autoimmune disease; Autoantigen epitope
Categories
Ask authors/readers for more resources
The research found that in the experimental autoimmune prostatitis model, significant relief of pelvic pain and prostatitis symptoms can be achieved by injecting anti-T2 polyclonal antibodies, indicating that T2 may be an important factor in the disease and contribute to a better understanding of the etiology of chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS).
Chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS) is a clinical tricky problem due to its enigmatic etiology, low cure rate, and high recurrence rate. The research on its pathogenesis has never stopped. In this experimental autoimmune prostatitis (EAP) model, male C57BL/6 mice were subcutaneously immunized with prostate extracts in an adequate adjuvant. For mice in the antibody intervention group, anti-T2 polyclonal antibodies were intraperitoneally injected during the induction of EAP. Animals were periodically monitored for pelvic pain. Hematoxylin and eosin staining was used to assess prostate inflammation. Tumor necrosis factor-alpha (TNF-alpha) levels in serum were measured by ELISA kits. The immunized animals developed prostatitis as a consequence of the immune response against prostate antigens. Pelvic pain thresholds were gradually decreased and TNF-alpha expression significantly increased. T2 plays an important role in the disease since polyclonal antibodies to T2 greatly ameliorated symptoms in animals induced for EAP. T2 peptide may represent the major autoantigen epitope in EAP, which could serve for a better understanding of the etiology of CP/CPPS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available